RS Research

Executive Summary

RS Research is a Swiss nanotechnology company headquartered in Zurich, founded in 2016, focused on developing Sagitta® targeted delivery platforms to improve the therapeutic index of oncology payloads. The platform aims to address the persistent efficacy-toxicity trade-off in cancer treatment by enhancing drug delivery to tumors while reducing systemic side effects. Currently in Phase 1 stage as a private entity, RS Research has not disclosed total funding or valuation. The technology has potential applicability across a broad spectrum of payloads, positioning the company in the competitive nanomedicine space. With no disclosed pipeline details, the company's progress and commercial viability remain to be validated through clinical data and strategic partnerships.

Upcoming Catalysts (preview)

• H1 2027Phase 1 clinical data readout for lead candidate40% success
• Q4 2026Strategic partnership or licensing deal30% success
• Q2 2027Series A or B funding round50% success